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Self-renewal and differentiation block are two key features of leukemic stem cells (LSCs) in mixed-lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML), which can originate from either hematopoietic stem cells (HSCs) or granulocyte macrophage progenitors (GMPs). We have previously demonstrated that β-catenin is essential for the establishment of MLL LSCs, where MLL-AF9 activates β-catenin, one role of which is to confer self-renewal capacity to GMPs, necessary for malignant transformation. 1 The effect of β-catenin appears to be largely context-dependent and driven by its upstream components that fine-tune the signal to modulate different functional programs downstream of β-catenin. 2 The targeting of critical upstream components could therefore serve as a potential strategy to effectively block β-catenin signaling. However, our understanding of upstream signaling events leading to β-catenin activation in leukemia still remains poor.
G proteins and G protein-coupled receptors have been implicated in playing crucial roles in multiple cancers, where specific members of this family influence self-renewal and tumorigenesis, largely through activation of β-catenin signaling. 2 The G protein subunit Gaq has recently been identified as a direct target of MLL-AF4, 3 and Dot1l-mediated H3K79 methylation marks are enriched at the Gaq locus in MLL-AF9 LSCs, 4 indicating a role for Gaq in MLL leukemia.
To determine if Gaq is functionally important in MLL AML, we first examined the effects of Gaq inhibition on active β-catenin expression and colony-forming capacity of pre-LSCs derived from MLL-AF9 transduced KLS (HSC-enriched Lin -CD127 -Sca-1 + c-Kit + ) and GMPs (Lin -CD127 -Sca-1 -c-Kit high CD16/32 high CD34 + ). 1 These pre-LSCs are a recognized-early stage of leukemia development that subsequently acquires additional events in vivo leading to a full-blown leukemia. 1 Stable knockdown of Gaq in pre-LSCs was achieved by lentiviral-mediated delivery of short hairpin RNA (shGaq). We found that all three individual shGaq reduced Gaq expression in KLS-derived pre-LSCs (KLS pre-LSC ) and GMP-derived pre-LSCs (GMP pre-LSC ) and as a result, Gaq knockdown led to a significant decrease in the levels of active β-catenin and colony formation (Figure 1a and b) .
We next explored the effect of pharmacological inhibition of Gaq on pre-LSCs and leukemic cells. In the presence of 40 μM GP antagonist 2A (GP), a selective inhibitory peptide of Gaq protein, 5 
KLS
pre-LSC exhibited a significant decrease in β-catenin expression associated with a 50% reduction in colony formation (Figure 1c We next tested the leukemogenic inhibitory potential of GP inhibition in vivo, by pre-treating leukemic cells ex vivo with GP (40 µM) for 2-4 days, and subsequently transplanting viable cells into sub-lethally irradiated recipient mice. In vivo BrdU labeling analysis at 8 days post-injection showed that 2-day GP pre-treatment led to impaired cell proliferation in both KLS leukemic and GMP leukemic cells (Figure 1f and g). Consistent with the in vitro clonogenic assays (Figure 1d and e) we observed a slightly more pronounced reduction in proliferation for GMP leukemic cells. Further survival analysis showed that 4-day GP pre-treatment was able to promote a small but significant enhancement of survival in mice transplanted with GMP leukemic cells (Figure 1h ), and genetic depletion of Gaq also significantly delayed the onset of leukemia induced by GMP leukemic cells (Figure 1i ). Together, this provides the first evidence that Gaq signaling contributes to maintenance of fully-developed AML. Furthermore, we found that the inhibitory effect of GP on human MLL-AF9 AML cells might largely depend on the expression levels of endogenous β-catenin, as we observed that GP selectively suppressed the growth of human THP-1 AML cells (Figure 1j ) that endogenously express β-catenin, 6 but had no effects on MOLM-13 cells (Figure 1j ) as well as other human AML cell lines (for example, ML2 carrying the MLL-AF6 translocation, data not shown), in which β-catenin expression is undetectable. 6 In contrast, ABT-199, a selective Bcl2 inhibitor, had a β-catenin-independent effect and inhibited the growth of these AML cell lines (Figure 1j ).
In an attempt to dissect the mechanism, by which Gaq inhibition causes impairment in MLL leukemogenesis, we performed gene-expression analysis using RNA from shGaq transduced KLS leukemic cells and found that several mitochondrial complex 1 genes (that is, mt-Nd2, mt-Nd4l and mt-Nd5) were down-regulated in Gaq knockdown cells, while the stress response and DNA damage repair gene Gadd45a was up-regulated ( Figure 2a ). The link between Gaq mRNA expression and the expression of mitochondrially-encoded Nd2 and Nd4l genes was confirmed in a panel of primary human AML samples (n = 84; Supplementary Table S1 ). Furthermore, activation of Gadd45a has been shown to occur as a result of activation of the FoxO family of transcription factors in response to oxidative stress. 7 Taken together, these data suggest a possible link between Gaq and mitochondrial function; therefore, we next sought to test whether Gaq inhibition affects the response of leukemic cells to mitochondrial stress. We first treated leukemic cells with the mitochondrial complex 1 inhibitor rotenone, which has been reported to increase reactive oxygen species (ROS) production triggering apoptosis. 8 Our results showed that ROS levels were slightly elevated in rotenone-treated KLS leukemic cells and were dramatically increased in rotenone-treated GMP leukemic cells (Figure 2b ). Gaq knockdown also dramatically increased ROS levels in GMP leukemic cells (Figure 2c ), suggesting a crucial role for Gaq activation in protecting GMP leukemic cells against oxidative stress. Gaq activity is important in GMP leukemic cells for maintaining basal oxidative phosphorylation (OXPHOS) levels and mitochondrial ATP production as Gaq inhibition, by either GP treatment or Gaq knockdown, significantly reduced the oxygen consumption rate (OCR, indicative of OXPHOS) and ATP levels in these cells, with a slightly reduced effect in KLS leukemic cells (Figure 2d-g ). Such a functional role for Gaq is in keeping with the positive correlation between expression of Gaq and levels of mitochondrial complex 1 gene expression, supporting the hypothesis that Gaq expression and function may be closely coupled to mitochondrial function in AML cells. It is worth noting that in MLL leukemic cells Gaq inhibition had similar effects to rotenone treatment on induction of ROS and suppression of OCR and colony formation (Figure 2b, d and h) .
In this study, we report a previously unknown role for Gaq in maintenance of MLL leukemia. Previous studies implicate Gaq as a MLL fusion target whose expression correlates with H3K79 methylation in MLL LSCs. 3, 4 The effect of Gaq inhibition on repression of MLL leukemic cell growth largely depends on endogenous β-catenin activity. This is consistent with our previous findings that aberrant activation of β-catenin is essential for self-renewal of MLL LSCs, whereas inhibition of β-catenin impairs LSC formation and MLL leukemia development.
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Here we describe a potential mechanism linking mitochondrial function to leukemogenesis via Gaq signaling activation (Supplementary Figure S2) . LSCs in AML rely primarily on OXPHOS to generate ATP for energy, 10 and our results show that Gaq inhibition can impair the energy-generating capacity of MLL leukemic cells, increase ROS levels and lead to activation of a stress response associated with activation of Gadd45a. Our data revealing reduced β-catenin levels following Gaq inhibition are consistent with the effects of Gaq on mitochondrial activity being mediated via β-catenin activity, as recent studies have shown the crucial role for β-catenin in mitochondrial energy metabolism, 11, 12 and β-catenin is also critical in HSC for suppression of ROS levels. MLL AML has a particular dependence on β-catenin activity 1 and the findings presented here raise the possibility that targeting of β-catenin and mitochondrial metabolism via Gaq may be a potential approach to reduction of leukemogenesis in MLL AML. Of note, while human AML represents a heterogeneous disease, the correlation of Gaq expression with expression of mitochondrially-encoded Nd2 and Nd4l genes provides support that Gaq-regulation of mitochondrial function may also be important in other AML subtypes. Whether activity of Gaq and/ or OXPHOS in human AML cells, or levels of mitochondrial complex 1 genes, are predictive of response to chemotherapy is still under investigation. Gaq-mediated signaling is likely to cooperate with other pathways to drive leukemogenesis. In particular, FLT3-ITD mutation accelerates the onset of MLL-AF9-induced AML and correlates with poor outcome in AML patients. 13 We have previously demonstrated that down-regulation of Gadd45a via FLT3-ITD contributes to the myeloid differentiation block in AML, 14 and strikingly the regulator of G protein signaling 2 (Rgs2), a potent negative regulator of Gaq function, 15 has also been shown to be a critical target gene down-regulated in FLT3-ITD-induced AML. 16 It is essential to investigate the mechanisms involved in G protein-associated regulation of β-catenin signaling in AML LSCs, as a number of studies have now shown that G-protein coupled signaling can be targeted therapeutically 15 and such an approach may provide clinical benefit for MLL AML patients. Future studies will identify predominant transducers in Gaq signaling and further define the role of β-catenin down-regulation, FoxO transcription factors and Gadd45a in the stress response associated with Gaq inhibition.
